Lanicemine (AZD6765) is an NMDA antagonist developed by the company AstraZeneca in hopes to help people with treatment-resistant depression. Let’s face it, if you have treatment-resistant depression, you are probably waiting for some sort of breakthrough in technology and/or a new class of drugs for treatment. Although many people find benefit from SSRI’s, TCA’s, and …
Lithium carbonate has become a very popular augmentation option for treatment-resistant depression. If you have treatment resistant depression, chances are that most psychiatrists have explored antidepressant monotherapy – or treatment with a single antidepressant. Once you have gone through the ringer of SSRI’s, TCA’s, and MAOI’s and found that none of the medications help your …
The use of stimulants like Adderall for cases of treatment-resistant depression is not very common these days. It is much more common for a psychiatrist to put the patient through the ringer of SSRI, SNRI, Tricyclic, and MAOI classes before they are likely to consider a psychostimulant. This is in part due to the fact …